Key facts
- It has raised $36.3M across 4 recorded rounds; the latest was Early Stage VC ($11.1M) in Apr 2023.
- Notable investors include Y Combinator, Founders Fund, Lux Capital, Pegasus Tech Ventures, The Engine — 34 tracked in total.
- Multiply Labs has filed 5 Form Ds with the SEC since 2017, most recently Apr 2023 ($11.1M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 34 names
- ·Watchlist + deal alerts for Multiply Labs
Funding rounds
4 roundsAbout Multiply Labs
Developer of advanced robotics technology designed to manufacture next-gen biological drugs and to address the biotech industry's scaling challenges. The company's system manufactures personalized pharmaceutical capsules that are tailor-made by robots at a fraction of the cost to the needs of each patient, enabling the pharmaceutical industry to get capsules based on the metabolic needs of the patients.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2016
- Employees
- 50
- Website
- multiplylabs.com/
- Ownership
- Privately Held (backing)
Multiply Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Multiply Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Multiply Labs in its N-PORT filings yet. We sweep new filings monthly.